Start with its own history
At 30.57×, AUROLAB.BO is 24.0% above its 10-observation annual average. A lower multiple can reflect a lower price, higher earnings, or weaker growth expectations—not necessarily a bargain.

Current valuation, historical context, and peer comparisons.
Current P/E ratio
30.57×
24.0% abovethe 10-year annual average
Price and EPS in quote currency. Calculation details
Investors are paying 30.57 for every 1 of reported earnings per share.
Annual period-end data · 19 observations
| Period end | P/E | Change |
|---|---|---|
| Mar 31, 2026 | 46.65× | -43.1% |
| Mar 31, 2025 | 82.00× | +489.8% |
| Mar 31, 2024 | 13.90× | -0.2% |
| Mar 31, 2023 | 13.94× | -36.6% |
| Mar 31, 2022 | 22.00× | +212.4% |
| Mar 31, 2021 | 7.04× | +45.7% |
| Mar 31, 2020 | 4.83× | -43.8% |
| Mar 31, 2019 | 8.60× | -45.9% |
| Period end | P/E | Change |
|---|---|---|
| Mar 31, 2018 | 15.90× | -49.8% |
| Mar 31, 2017 | 31.68× | +122.8% |
| Mar 31, 2016 | 14.22× | +154.1% |
| Mar 31, 2015 | 5.60× | -12.7% |
| Mar 31, 2014 | 6.41× | -4.0% |
| Mar 31, 2013 | 6.67× | -49.6% |
| Mar 31, 2012 | 13.24× | -33.4% |
| Mar 31, 2011 | 19.88× | -45.6% |
| Mar 31, 2010 | 36.54× | +46.2% |
| Mar 31, 2009 | 25.00× | -63.0% |
| Mar 31, 2008 | 67.57× | N/M |
Change is relative to the preceding observation. N/M values are excluded from averages.
Company P/E vs. peer trailing-12-month ratios
| Company | P/E ratio |
|---|---|
AUROLAB.BO This stockAuro Laboratories Limited | 30.57× |
AUROPHARMA.NSAurobindo Pharma Limited | 26.37× |
VRL.BOVasundhara Rasayans Limited | 7.70× |
AAREYDRUGS.NSAarey Drugs & Pharmaceuticals Limited | 73.73× |
PANCHSHEEL.BOPanchsheel Organics Limited | 13.53× |
SYSCHEM.BOSyschem (India) Limited | 21.96× |
GODAVARI.BOGodavari Drugs Limited | 23.38× |
LASA.NSLasa Supergenerics Limited | N/M |
MANGALAM.NSMangalam Drugs & Organics Limited | N/M |
Peers are selected by the data provider. Business models and earnings definitions can differ.
Put the numbers in context
At 30.57×, AUROLAB.BO is 24.0% above its 10-observation annual average. A lower multiple can reflect a lower price, higher earnings, or weaker growth expectations—not necessarily a bargain.
The median of the 6 positive peer ratios above is 22.67×. Check growth, margins, debt, and earnings quality before interpreting the gap. A faster-growing business may justify a higher multiple.
One-off gains can temporarily lower P/E; unusual charges can raise it. Reported earnings and forward estimates answer different questions. Pair this view with return on equity and liquidity for a fuller picture.
Keep your research connected
Pull historical P/E into Excel or Google Sheets with Wisesheets. Build your own comparisons alongside the rest of your financial model.
Explore Wisesheets=WISE("AUROLAB.BO", "PE Ratio", "LQ")Share price 229.9 ÷ EPS 7.52 = 30.57×. Data is supplied by Financial Modeling Prep through Wisesheets. Quote feed updated Nov 11, 2026; this is not a real-time trading quote.
Annual and quarterly P/E observations are provided separately from the current quote. Averages use the latest 3, 5, or 10 annual observations, excluding missing and nonpositive ratios. Pre-IPO observations are omitted. These are period-end observations, not daily averages.
The current quote feed does not specify the exact EPS filing-period end or whether EPS is basic or diluted. We do not label it as forward P/E. Peer ratios are explicitly trailing-12-month (TTM) values. Historical observations do not include independently verified price and EPS inputs. Sources may update on different schedules; rounded inputs can produce small calculation differences. Historical comparisons describe past pricing, not an estimate of fair value.
The essentials behind the numbers.